A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass
about
HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseasesSerum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cystsCurrent clinical application of serum biomarkers to detect ovarian cancerIn 2014, can we do better than CA125 in the early detection of ovarian cancer?The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomasProteomics of ovarian cancer: functional insights and clinical applicationsComprehensive serum profiling for the discovery of epithelial ovarian cancer biomarkersReply to comment of Prof. Artur CzekierdowskiGlycoprofiling of cancer biomarkers: Label-free electrochemical lectin-based biosensors.Strategies to diagnose ovarian cancer: new evidence from phase 3 of the multicentre international IOTA study.Towards an evidence-based approach for diagnosis and management of adnexal masses: findings of the International Ovarian Tumour Analysis (IOTA) studiesDevelopment of nanoscale approaches for ovarian cancer therapeutics and diagnosticsEvaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study.Integration of cell phone imaging with microchip ELISA to detect ovarian cancer HE4 biomarker in urine at the point-of-careUsefulness of diagnostic indices comprising clinical, sonographic, and biomarker data for discriminating benign from malignant ovarian masses.The Use of Human Epididymis 4 and Cancer Antigen 125 Tumor Markers in the Benign or Malignant Differential Diagnosis of Pelvic or Adnexal Masses.Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) - a study of the TOC ConsortiumPrimary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis.MUC16 (CA125): tumor biomarker to cancer therapy, a work in progressp53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass.Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer.Preoperative evaluation of risk of ovarian malignancy algorithm index in prediction of malignancy of adnexal massesElafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors.Improved blood tests for cancer screening: general or specific?The serum glycome to discriminate between early-stage epithelial ovarian cancer and benign ovarian diseases.Matrix-assisted laser desorption/ionization imaging mass spectrometry: a promising technique for reproductive research.Proteomics and ovarian cancer: integrating proteomics information into clinical careImproving strategies for diagnosing ovarian cancer: a summary of the International Ovarian Tumor Analysis (IOTA) studies.Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis.CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease.Presurgical diagnosis of adnexal tumours using mathematical models and scoring systems: a systematic review and meta-analysis.Development of multiplexed bead-based immunoassays for the detection of early stage ovarian cancer using a combination of serum biomarkersMeasurement of phospholipids may improve diagnostic accuracy in ovarian cancerHE4 as a biomarker for ovarian and endometrial cancer management.Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass.HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm.A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.Comparison of HE4, CA125, and ROMA Diagnostic Accuracy: A Prospective and Multicenter Study for Chinese Women With Epithelial Ovarian Cancer.Co-expression of Lewis y antigen with human epididymis protein 4 in ovarian epithelial carcinoma
P2860
Q24634978-9319DD3D-4366-49C2-BC10-F905B859491BQ24651331-570B3679-38E0-4B88-863E-4B809A53A2BAQ26768709-69964C46-5F54-458E-8298-E76E8FDDB5BCQ26825152-F2B4D58A-2A0D-4140-960A-61C2B2F5A5B9Q26992102-59F48FAE-9252-4A60-9604-5BD669B2A248Q28082632-6C47A456-0846-4A88-BEEF-72F2FE46C3B1Q28741004-3A8BFB9B-BA8A-4703-A49F-A09E013B1FD8Q30355814-6B514FE8-29A1-4C7C-B60D-B79C324BCAECQ30382105-72EB0C68-5C87-49BB-8E4F-9B24480C439FQ30404969-E88ED5B0-0696-489B-AD71-1DB6E3121173Q30414041-D9110065-B00E-49BF-89F6-DB34462DCEFEQ30421664-2398D575-394D-44F0-BE1A-9E7ADFB2CB8AQ30428244-EB5CEFC5-2605-494A-9FAE-522FF27D36BEQ30449569-8983562B-B9C2-4583-98FB-5B1081F9A188Q30885682-80F91DC4-8A50-4DEA-B46A-1380E0F8A965Q33572029-5E38A263-7D48-4A35-A9C4-F9F4B6A27E08Q33624809-C91B68A6-E621-458C-A2FD-4451F63A3E56Q33690390-3889D376-9F1D-47A3-B5F3-6D87341EEAF3Q33713506-74B48D54-DCC4-4BE0-AD62-86464215FC70Q33725961-F14DD33C-3CEF-420B-9121-B6FEDE1E7F2AQ33862961-488A799C-91A2-4E75-B4E6-BDAA06B82A09Q33907528-DA91A342-1063-40DF-ACEB-9C53F0874EDCQ33918256-F6CB73E0-22B9-4AC3-BC26-C0200CEF9C60Q33955266-03E7080E-B2AC-4F43-9101-396274C1A0F6Q34086617-0CA4EB07-F9B5-445C-BFCE-1B4CAC0A5836Q34092935-1849E10A-9304-4666-870B-2B40A9028C0DQ34096121-FD9AFEAC-1F2B-4005-838A-54294914E9B9Q34126627-0BE77950-C89E-475C-9364-035FCA7DA485Q34306120-C35472F5-FD53-4CBB-AC2B-DA1D6B449E6DQ34308808-CD25B7DF-9EAA-4F07-81BC-C35DC559F8F9Q34334247-32A5823F-106F-4BA8-AD19-21D298A3C2D4Q34391119-350C9827-57C9-4F50-8861-B8ABAFF1FBA7Q34412873-27339004-F524-4535-8AC9-FD7A778D8F10Q34451931-B86EFD4E-1704-49AA-9B9C-DF5592604914Q34611530-97FF40D4-EC9B-4218-98AF-AEF6B3653888Q34619636-7328FA87-219A-43AA-82C6-7ACECC899195Q34621826-2F95BAE8-75C1-4757-8806-891837D4CEE1Q34672941-E7AB9790-CA2E-4996-8AAC-0F0B779AEDFAQ34675023-0BC66859-129E-49B4-B3CC-F0CD3E06C60EQ34873791-F45A7B05-293C-4AD0-873C-E9F9D6F501AE
P2860
A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
A novel multiple marker bioass ...... in patients with a pelvic mass
@ast
A novel multiple marker bioass ...... in patients with a pelvic mass
@en
type
label
A novel multiple marker bioass ...... in patients with a pelvic mass
@ast
A novel multiple marker bioass ...... in patients with a pelvic mass
@en
prefLabel
A novel multiple marker bioass ...... in patients with a pelvic mass
@ast
A novel multiple marker bioass ...... in patients with a pelvic mass
@en
P2093
P2860
P1433
P1476
A novel multiple marker bioass ...... in patients with a pelvic mass
@en
P2093
Amy K Brown
D Scott McMeekin
M Craig Miller
Paul DiSilvestro
Richard G Moore
Robert C Bast
Robert Kurman
Steven J Skates
W Jeffrey Allard
Walter Gajewski
P2860
P356
10.1016/J.YGYNO.2008.08.031
P407
P577
2008-10-12T00:00:00Z